In COVID-19 clinical update #65, Daniel Griffin summarizes effects of non-pharmaceutical interventions, updated summer camp guidance from CDC, serology testing not recommended by FDA, antigen tests during a music event, inhibition of vaccine immunogenicity by methotrexate, phase 3 trial results for colchicine, and small airway disease as a post-acute sequelae.
In COVID-19 clinical update #64, Daniel Griffin covers new guidance from NY on day camps, mitigation and infection rates in schools, testing to sustain in person instruction, Moderna mRNA vaccine highly effective in adolescents, longer storage of Pfizer vaccine, FDA EUA for sotrovimab, and persistent illness in UK children.
In COVID-19 clinical update #63, Daniel Griffin reviews cases at child care facilities, estimates of mRNA vaccine effectiveness, risk of reinfection in university students, enhanced antibody generation with extended interval of mRNA vaccination, no benefit of convalescent plasma in hospitalized patients, and risk of clinical sequelae after acute infection.
TWiV reveals that 2% of SARS-CoV-2−positive individuals carry 90% of the virus circulating in a college campus, and a nanoparticle vaccine that induces cross-reactive immunity against multiple pandemic and pre-emergent coronaviruses.
In COVID-19 clinical update #62, Daniel Griffin covers outdoor transmission of the virus, safe use of NSAIDS, expansion of Pfizer/BioNTech vaccine to include 12-15 year olds, post-disease Mucormycosis, and hydroxychloroquine treatment associated with increased mortality.
TWiV revisits Brazil’s rejection of Sputnik vaccine, examines influenza transmission via the air from the nasal epithelium of ferrets, and a history of accidental releases of polioviruses and their relevance for eradication of poliomyelitis.
In COVID-19 clinical update #61, Daniel Griffin reviews a modeling of future hospitalizations and deaths by vaccination rates and non pharmaceutical intervention scenarios, performance evaluation of rapid antigen tests, children making up a growing share of new cases, antibody response to mRNA vaccine in solid organ transplant recipients, and outcomes in hospitalized patients treated with tocilizumab.
The TWiVmeisters discuss how copy-back defective viral genomes might modulate the clinical outcome of respiratory syncytial virus infection, and detection of antibodies to henipa- and filo-like viruses in Trinidad bats.
In COVID-19 clinical update #60, Daniel Griffin summarizes CDC guidance for summer camps, how to protect yourself when fully vaccinated, updated recommendation for J&J vaccine, declining global case fatality rate, and characterization of post-acute sequelae.
A TWiV trio explains a method for sequencing single genomes of SARS-CoV-2 and its use to explore in-host evolution drive by antibody responses, and incidence of cerebral venous thrombosis in COVID-19 patients and vaccine recipients.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Dickson D.
Despommier, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Jolene Ramsey, Ph.D.